Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who satisfy both of the following diagnostic criteria:~  1. Diagnosis of Dementia due to Alzheimer's Disease according to DSM-5.~ 2. Diagnosis of Probable Alzheimer's Disease according to NINCDS-ADRDA.~* Hospitalized patients or care facility patients or care at home patients~* Patients with an MMSE score of 1 to 22~* Patients who have the agitation defined according to the Consensus provisional definition of agitation in cognitive disorders from the International Psychogeriatric Association (IPA)~Exclusion Criteria:~* Patients who have dementia other than dementia of the Alzheimer's type~* Patients diagnosed with delirium between 30 days before the screening examination and baseline evaluation according to DSM-5.~* Patients diagnosed with any of the following disorders according to DSM-5:~  * Schizophrenia spectrum and other psychotic disorders~ * Bipolar and related disorders~ * Major depressive disorder

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole, 1mg/day (Type: EXPERIMENTAL): Drug: 1mg/day Once daily for 10 weeks
- Brexpiprazole, 2mg/day (Type: EXPERIMENTAL): Drug: 2mg/day Once daily for 10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Placebo (0mg/day) Once daily for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).